1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine: Negative Control for Src Kinase Pathway Research

Executive Summary: 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (SKU B7190, APExBIO) is a DMSO-soluble small molecule negative control for the Src kinase inhibitor PP 2, supporting precise kinase signaling pathway research (APExBIO). It exhibits a molecular weight of 211.22 and a chemical formula of C₁₁H₉N₅ (CAS No. 5334-30-5). The compound is supplied at ≥98.00% purity with full documentation and must be stored at -20°C for optimal stability. Its use enables robust discrimination of on-target effects in protein tyrosine kinase inhibition and signal transduction studies (Shvetsova et al., 2025). 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is for research use only and is not approved for diagnostic or clinical applications.

Biological Rationale

Protein tyrosine kinases such as Src play pivotal roles in cellular signaling, proliferation, and differentiation. Dysregulated Src kinase activity is implicated in cancer, cardiovascular, and neurodegenerative diseases (Shvetsova et al., 2025). Accurate signal transduction studies require negative controls to confirm the specificity of kinase inhibitors and to distinguish on-target from off-target effects. 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, as the negative control for PP 2, is critical for validating results in kinase pathway research, particularly in complex cellular contexts.

Mechanism of Action of 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is structurally similar to PP 2 but lacks Src kinase inhibitory activity. This enables its deployment as a negative control in experiments evaluating Src-mediated phosphorylation events. When used alongside PP 2, it allows unambiguous attribution of observed cellular effects to Src kinase inhibition, rather than to potential off-target or vehicle effects (see detailed mechanistic discussion; this article expands on the context of vascular biology not fully covered in the prior piece). The compound does not interfere with L-type voltage-gated Ca²⁺ channels or other kinases at standard assay concentrations (typically 10 μM), establishing assay specificity (Shvetsova et al., 2025).

Evidence & Benchmarks

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (10 μM) does not inhibit Src kinase activity in in vitro and ex vivo arterial contraction assays, serving as a validated negative control (Shvetsova et al., 2025, https://doi.org/10.1080/10715762.2024.2448483).
• PP 2 (10 μM) inhibits methoxamine-induced contraction in rat saphenous artery, while 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine does not, confirming its lack of Src kinase inhibition (Shvetsova et al., 2025, DOI).
• The compound is DMSO soluble up to at least 10 mM and remains stable at -20°C, provided solutions are freshly prepared (APExBIO product data).
• Negative control deployment in kinase inhibitor studies is recommended by community guidelines to reduce false-positive results and increase reproducibility (review).
• The negative control does not alter NADPH oxidase-derived ROS signaling or L-type Ca²⁺ channel activity in early postnatal rat arterial tissue (Shvetsova et al., 2025, DOI).

Applications, Limits & Misconceptions

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine is essential for:

• Discriminating on-target (Src kinase-specific) from off-target effects in kinase pathway and cell signaling research (see role in specificity; this article updates with new vascular evidence).
• Validating PP 2-dependent findings in cancer biology and signal transduction models.
• Supporting robust experimental design in protein tyrosine kinase inhibition assays.
• Enhancing reproducibility in studies of cell proliferation, differentiation, and vascular contraction.

Common Pitfalls or Misconceptions

• Not a Src kinase inhibitor: It does not block Src or related kinases at standard concentrations.
• Not a diagnostic or clinical compound: For research use only; not for human or animal therapeutic use (APExBIO).
• Does not affect L-type Ca²⁺ channels: Unlike LTCC blockers (e.g., nimodipine), it has no impact on calcium influx.
• Solutions not stable long-term: Freshly prepare solutions; avoid storage of dissolved compound for more than a few hours at room temperature or days at -20°C.
• Cannot substitute for vehicle controls: Should be used in conjunction with, not in place of, vehicle-only controls.

Workflow Integration & Parameters

For optimal results, dissolve 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine in DMSO to a stock concentration (e.g., 10 mM), then dilute to the working concentration immediately prior to use. Typical working concentrations in kinase assays range from 1–10 μM. Store powder at -20°C; ship with blue ice. Use only freshly prepared solutions to avoid degradation. Include both PP 2 and negative control arms in experimental workflows to ensure specificity (discussion of workflow best practices; this article provides updated reagent stability data).

Conclusion & Outlook

1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (APExBIO, B7190) remains the gold-standard negative control for Src kinase inhibitor PP 2 in signal transduction and cancer biology research. Its well-defined specificity, high purity, and robust documentation enhance reproducibility and experimental confidence. Future studies may further clarify its role in emerging kinase pathway models and complex multicellular systems. For the most up-to-date protocols and ordering information, visit the APExBIO product page.